The analysis and management of factors that form pharmaceutical care for diabetes patients in Ukraine
DOI:
https://doi.org/10.15587/2313-8416.2016.64836Keywords:
pharmaceutical care, anti-diabetic remedies, individual medical needAbstract
Aim. To analyze the factors that form pressing questions about the management of pharmaceutical care for diabetes patients and to substantiate the ways of its optimization.
Methods. Marketing methods; pharmaceutical informatics methods: determination of information needs, the search and systematization of evidence-based information about remedies, pharmaceutical computer databases development; data synthesis and generalization methods.
Results. The analysis of the theoretic arsenal of anti-diabetic remedies in Ukraine during 2002-2016 years and its quantitative growth from 117 to 364 medicines has been carried out and determined by the developed method. The highest growth dynamics was registered in insulin analogues group (from 0 to 18 remedies). By analyzing computer medicinal passports of diabetes patients a lack of modern treatment regimens use has been registered. A sharp decrease of “Rosiglitazonum” highly effective anti-diabetic remedy use since 2007 and stop using in 2010 has been determined, and the influence of evidence-based medicine results on this process has been studied. The fact of insufficient informing of medical and pharmaceutical specialists in Ukraine about pharmaceutical care for diabetes patients has been found.
Conclusion. In general, theoretical arsenal of anti-diabetes remedies in Ukraine meets the international standards and recommendations about diabetes treatment requirements, while practical pharmacotherapy needs improvement. Evidence-based medicine results should be used to determine perspective need for anti-diabetic medicines. For optimization of pharmaceutical care system for diabetes patients in Ukraine it is necessary to establish specialized pharmacies and to study training program for pharmaceutical specialists
References
IDF diabetes atlas – 7th edition. Available at: https://www.idf.org/diabetesatlas
Dovidnyk osnovnyh pokaznykiv dijal'nosti endokrynologichnoi' sluzhby Ukrai'ny za 2002 r. (2002). Endokrynologija. Kyiv, 1, 24.
Dovidnyk osnovnyh pokaznykiv dijal'nosti endokrynologichnoi' sluzhby Ukrai'ny za 2014 r. Dodatok 1 (2015). Endokrynologija. Kyiv, 20 (1), 38.
O Programme po diabetu. Available at: http://www.who.int/diabetes/goal/ru/
Type 2 diabetes in adults: management. NICE guidelines [NG28] (2015). National Institute for Health and Care Excellence. Available at: http://www.nice.org.uk/guidance/ng28
Derzhavnyj rejestr likars'kyh zasobiv Ukrai'ny. Available at: http://www.drlz.kiev.ua/ibp/ddsite.nsf/all/zak01
IDF Treatment Algorithm for People with Type 2 Diabetes. Available at: http://www.idf.org/treatment-algorithm-people-type-2-diabetes
British National Formulary (№ 67) (2014). BMJ Group and RPS Publishing, 1127.
FDA approves Afrezza to treat diabetes (2014). FDA press release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm
Bojko, A. I. (2006). Marketyngovi ta farmakoekonomichni doslidzhennja likars'kyh zasobiv dlja likuvannja diabetu. Lviv, 20.
Bojko, A. I., Plodnik, V. Je. (2011). Porivnjal'nyj analiz arsenalu protydiabetychnyh likars'kyh zasobiv v Ukrai'ni ta Pol'shhi. Kyiv, 20, 700–708.
Bojko, A. I. (2012). Suchasna tendencija do farmakoterapii' hvoryh z infekcijnym i neinfekcijnym zahvorjuvannjam odnochasno: farmacevtychna skladova. Farmacevtychnyj chasopys, 1, 64–68.
Prokopishin, V. I., Safta, V. N. (1980). Osnovnye faktory, formirujushhie potreblenie lekarstv i ih sistemnaja klassifikacija. Farmacija, 29 (2), 1–6.
Dremova, N. B., Kobzar', L. V. (1992). Osnovnye napravlenija issledovanija nauchnogo prognozirovanija potreblenija lekarstvennyh sredstv. Farmacija, 2, 7–9.
Dryomova, N. B., Kobzar, L. V., Korzhavych, E. A. (2015). Methodology of domestic studies of medicinal drugs need and their consumption. Pharmacy & Pharmacology, 3, 4–9. doi: 10.19163/2307-9266-2015-3-3(10)-4-9
Nissen, S. E., Wolski, K. (2007). Effect of rosiglatazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356 (24), 2457–2471. doi: 10.1056/nejmoa072761
Bojko, A. I. (2013). Opracjuvannja koncepcii' ta cil'ovoi' programy regional'nogo Proektu “Informatyzacija recepturnogo obigu protydiabetychnyh likars'kyh zasobiv v Ukrai'ni”. Farmacevtychnyj chasopys, 2 (26), 72–75.
Bojko, A. I. (2012). Avtors'ka navchal'na programa cyklu tematychnogo udoskonalennja “Informatyzacija recepturnogo obigu v Ukrai'ni” dlja provizoriv za special'nostjamy “Zagal'na farmacija” ta “Organizacija i upravlinnja farmacijeju”. Lviv.: Vyd-vo LNMU, 19.
Bojko, A. I. (2015). Avtors'ka navchal'na programa cyklu tematychnogo udoskonalennja “Informatyzacija farmacevtychnoi' dopomogy hvorym na cukrovyj diabet” dlja provizoriv za special'nostjamy “Zagal'na farmacija” ta “Organizacija i upravlinnja farmacijeju”. Lviv.: Vyd-vo LNMU, 21.
Bojko, A. I., Parnovs'kyj, B. L., Jackova, G. Ju. et. al (2012). Zbir ta opracjuvannja danyh pro vzajemodiju likars'kyh zasobiv dlja komp’juternyh informacijnyh system. Aktual'ni pytannja farmacevtychnoi' i medychnoi' nauky ta praktyky, 1, 86–90.
Bojko, A. I. (2015). Komp’juterni tehnologii' v optymizacii' likars'kogo zabezpechennja hvoryh na cukrovyj diabet. Novyny medycyny ta farmacii', 12 (547), 15.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Андрій Ігорович Бойко
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
